Instil Bio News

Instil Bio, Inc. Q1 Loss Decreases

RTTNewsMay 10 20:10

Instil Bio | 10-Q: Quarterly report

Futu NewsMay 10 19:14 · Announcements

Instil Bio Q1 2024 GAAP EPS $(2.39) Misses $(2.23) Estimate

Instil Bio (NASDAQ:TIL) reported quarterly losses of $(2.39) per share which missed the analyst consensus estimate of $(2.23) by 7.17 percent.

BenzingaMay 10 19:06

Instil Bio 1Q Research and Development Expenses $7.3M >TIL

Instil Bio 1Q Research and Development Expenses $7.3M >TIL

Dow JonesMay 10 19:01

Press Release: Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update DALLAS, May 10, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (Nasdaq: TIL), a clinical-stage biopharmaceu

Dow JonesMay 10 19:00

Instil Bio 1Q Loss/Shr $3.74 >TIL

Instil Bio 1Q Loss/Shr $3.74 >TIL

Dow JonesMay 10 19:00

Instil Bio Announces Board Reshuffle Following Resignation

TipRanksApr 27 04:14

Instil Bio Cut to Hold From Buy by Jefferies

Instil Bio Cut to Hold From Buy by Jefferies

Dow JonesApr 12 21:34

Jefferies Investment Bank: Downgraded the Instil Bio (TIL.US) rating from buy to hold, and adjusted the target price from $5.00 to $11.00.

Jefferies Investment Bank: Downgraded the Instil Bio (TIL.US) rating from buy to hold, and adjusted the target price from $5.00 to $11.00.

Zhitong FinanceApr 12 21:30

Jefferies Downgrades Instil Bio to Hold, Raises Price Target to $11

Jefferies analyst Kelly Shi downgrades Instil Bio (NASDAQ:TIL) from Buy to Hold and raises the price target from $5 to $11.

BenzingaApr 12 21:24

Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Instil Bio (TIL) and Regeneron (REGN)

TipRanksApr 12 17:20

HC Wainwright & Co. Reiterates Buy on Instil Bio, Maintains $18 Price Target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy and maintains $18 price target.

BenzingaMar 25 18:08

Instil Bio Non-GAAP EPS of -$1.26 Beats by $2.14

Seeking AlphaMar 22 16:09

Instil Bio Q4 Adj EPS $(1.26) Beats $(2.85) Estimate

Instil Bio (NASDAQ:TIL) reported quarterly Adj losses of $(1.26) per share which beat the analyst consensus estimate of $(2.85) by 55.79 percent.

BenzingaMar 22 05:08

Instil Bio Sees Cash Runway Beyond 2026 >TIL

Instil Bio Sees Cash Runway Beyond 2026 >TIL

Dow JonesMar 22 05:04

Instil Bio 4Q Loss/Shr $1.99 >TIL

Instil Bio 4Q Loss/Shr $1.99 >TIL

Dow JonesMar 22 05:02

Press Release: Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update DALLAS, March 21, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (Nasdaq: TIL), a clinical-s

Dow JonesMar 22 05:00

Instil Bio Executives Secure Retention Bonus Agreements

TipRanksFeb 15 05:26

Analysts' Top Healthcare Picks: Instil Bio (TIL), Evolus (EOLS)

TipRanksJan 23 04:30

Instil Bio Is Maintained at Buy by HC Wainwright & Co.

Instil Bio Is Maintained at Buy by HC Wainwright & Co.

Dow JonesJan 22 19:17